Last reviewed · How we verify
Influenza split vaccine
A split influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against inactivated influenza virus antigens.
A split influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against inactivated influenza virus antigens. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Influenza split vaccine |
|---|---|
| Also known as | Shenzhen Aventis Pasteur, Hualan Biologicals |
| Sponsor | Hualan Biological Engineering, Inc. |
| Drug class | Inactivated split influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Split vaccines contain disrupted influenza virions that expose internal and surface antigens without intact infectious particles. This formulation triggers both humoral (antibody) and cell-mediated immune responses, providing protection against seasonal influenza strains included in the vaccine composition. The split design reduces reactogenicity compared to whole-virion vaccines while maintaining immunogenicity.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) (PHASE1)
- Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE2)
- A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE1)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |